The critical mass of biosimilars in the US is surely getting there. My opinion: now it’s time for price competition. Otherwise you have to ask, what was the point of it all? Maybe I’m just a naive foreigner. But US patients deserve better. #ACR23 @US_FDA session @RheumNow https://t.co/enHY6xffMa